Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Harnessing advanced data analysis for early detection, prevention and better outcomes
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
These abstracts report on the company's three lead drug candidates, including olverembatinib
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
It is the first autotaxin inhibitor to be investigated in cancer patients
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Subscribe To Our Newsletter & Stay Updated
